Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FK-GI101
- Development stage
- Preclinical
- Lead developer
- CellVax Therapeutics
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intradermal
01
Overview
FK-GI101 is a patient-specific, autologous cell-based immunotherapy developed for the treatment of gastrointestinal cancers, including gastric, pancreatic, and colon cancer. The drug is created by harvesting a patient's own tumor cells during surgery, which are then genetically modified in a lab to express Major Histocompatibility Complex (MHC) Class II molecules to enhance immune system recognition. These cells are irradiated to prevent replication and then re-administered to the patient, with the objective of activating a robust, personalized immune response targeting residual or recurring tumor cells[1][4]. The underlying technology is based on a proprietary platform developed by CellVax Therapeutics, and the drug targets tumors via improved antigen presentation to both CD4+ and CD8+ T-cells[4].
- Brand names
- FK-GI101FK-GI-101FK-GI 101
- Other names
- FK-GI101FK-GI-101FK-GI 101
02
Targets
CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on FK-GI101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FK-GI101.